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Abstract
We describe the small-scale, laboratory-based, production and quality control of a cocktail, consisting of exclusively lytic
bacteriophages, designed for the treatment of Pseudomonas aeruginosa and Staphylococcus aureus infections in burn
wound patients. Based on succesive selection rounds three bacteriophages were retained from an initial pool of 82 P.
aeruginosa and 8 S. aureus bacteriophages, specific for prevalent P. aeruginosa and S. aureus strains in the Burn Centre of the
Queen Astrid Military Hospital in Brussels, Belgium. This cocktail, consisting of P. aeruginosa phages 14/1 (Myoviridae) and
PNM (Podoviridae) and S. aureus phage ISP (Myoviridae) was produced and purified of endotoxin. Quality control included
Stability (shelf life), determination of pyrogenicity, sterility and cytotoxicity, confirmation of the absence of temperate
bacteriophages and transmission electron microscopy-based confirmation of the presence of the expected virion
morphologic particles as well as of their specific interaction with the target bacteria. Bacteriophage genome and proteome
analysis confirmed the lytic nature of the bacteriophages, the absence of toxin-coding genes and showed that the selected
phages 14/1, PNM and ISP are close relatives of respectively F8, wKMV and phage G1. The bacteriophage cocktail is currently
being evaluated in a pilot clinical study cleared by a leading Medical Ethical Committee.
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Introduction
In burn wound care, bacterial infection remains a major
therapeutic problem and renders large numbers of thermal injuries
virtually untreatable. Whereas Staphylococcus aureus remains a
common cause of early burn wound infection, Pseudomonas
aeruginosa is known as the most common and lethal infectious
agent in burn centres, essentially due to its intrinsic and acquired
resistance to antibiotics [1–3].
To improve burn wound patient care, research at the
Laboratory for Molecular and Cellular Technology (LabMCT)
of the Burn Centre of the Queen Astrid Military Hospital in
Neder-over-Heembeek (Brussels), Belgium is investigating alterna-
tives for the treatment of infections with multidrug resistant
(MDR) infectious agents, like (bacterio)phage therapy. The use of
bacteriophages against bacterial pathogens was first proposed by
d’He´relle in 1917 [4] and has a long and convoluted history.
Currently, phage therapy is the subject of renewed interest, as a
consequence of the continuing increase in antibiotic resistance
worldwide [5], illustrated by the growing number of scientific
papers and text books [6–12].
However, major obstacles for the clinical application of
bacteriophages are the perception of viruses as ‘enemies of life’
[13], the lack of a specific frame for phage therapy in the current
Medicinal Product Regulation [14] and the absence of well-
defined and safe bacteriophage preparations.
To evaluate the safety and efficacy of bacteriophages in the
treatment of burn wound infections in a controlled clinical trial, we
prepared a highly purified and fully defined bacteriophage cocktail
(BFC-1), active against the P. aeruginosa and the S. aureus strains
actually circulating in the Burn Centre of the Queen Astrid
Military.
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To our knowledge the present paper describes for the first time,
in detail - from the initial bacteriophage isolation to the final
composition - a laboratory-based production of a well-defined
bacteriophage cocktail.
Methods
A flow chart of the entire BFC-1 production process and quality
control tests is depicted in Figure 1.
Titration of bacteriophage suspensions using the agar
overlay method
The bacteriophage titre was determined by assaying decinormal
serial dilutions (log(0) to log(212)) of the bacteriophage suspen-
sions with the agar overlay method [27,28]. One ml of each
dilution was mixed with 2.5 ml molten (45uC) Luria Bertani (LB)
(Becton Dickinson, Erembodegem, Belgium), containing 0.7% top
agar (Bacto agar, Becton Dickinson), and a suspension of
bacteriophage sensitive bacteria (end concentration of 108 cfu/
Figure 1. Flow chart of the BFC-1 production and final quality control.
doi:10.1371/journal.pone.0004944.g001
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ml) in sterile 14 ml tubes (Falcon, Becton Dickinson). This mixture
was plated in triplicate onto 90 mm diameter Petri dishes
(Plastiques Gosselin, Menen, Belgium) filled with a bottom layer
of 1.5% LB agar and incubated for 18–24 h at 37uC. To estimate
the original bacteriophage concentration, plates with one to 100
distinguishable homogenous plaques were counted depending on
the phage plaque size. The mean was then calculated for the
triplicate plates.
Initial isolation, separation and purification of P.
aeruginosa and S. aureus lytic bacteriophages
The bacteriophage sensitive strains used during the production
and quality control of BFC-1 are P. aeruginosa strain ‘573’, were
isolated at the Eliava Institute of Bacteriophage, Microbiology and
Virology (EIBMV) in the 1970s from bone marrow interstitial
fluid, and S. aureus strain ’13 S44 S9, isolated at the Brussels Burn
Centre in 2006 from a burn wound. Initially, S. aureus strain Wood
60 (EIBMV collection) was used for propagation of phage ISP, but
for the production of this cocktail the phage was propagated on S.
aureus 13 S44 S. The absence of temperate phages from the host
strains was tested as described in a separate section of this paper.
For bacteriophage isolation from natural samples such as
sewage and river water, one millilitre of 106concentrated LB
Broth (Becton Dickinson), 1 ml ‘host bacteria’ suspension,
containing 108 cfu in LB broth and 9 ml sewage or river water
were mixed in a 14 ml sterile tube. This tube was incubated at
37uC for 1.5–2 h. Subsequently, 200 ml of chloroform (Sigma-
Aldrich, Bornem, Belgium) was added and the tube was further
incubated at 4uC for 1 h. The lysate was aspirated with a sterile
5 ml syringe and passed through a 0.45 mm membrane filter
(Minisart, Sartorius, Vilvoorde, Belgium). Bacteriophages were
titrated using the agar overlay method, as described above. All
plaques with different morphology were touched with a sterile
pipette tip, inoculated into 2 ml of sterile LB broth in 14 ml sterile
tubes and incubated at 37uC for 2 h. Subsequently, 50 ml of
chloroform was added and the tube(s) were incubated at 4uC for
1 h. For each tube, a dilution series (log(0)2log(24)) was made in
sterile 14 ml tubes filled with LB broth. Each dilution was titrated
using the agar overlay method. Plates showing 1–10 plaques were
analysed in detail. Again, all plaques with different morphology
were touched with a sterile pipette tip, inoculated into 2 ml of
sterile LB broth in 14 ml sterile tubes and incubated at 37uC for
2 h. This complete cycle was repeated until one plaque
morphotype was obtained (homogeneous plaques).
In the case of bacteriophage ISP, which was isolated in the
1920s, porcelain, rather than membrane filters were employed.
Production of bacteriophage stocks
Bacteriophage stocks were prepared using the double-agar
overlay method with minor modifications. One millilitre of lysate
(see above) containing 103–105 plaque forming units (pfu) of
bacteriophages was mixed with 2.5 ml molten (45uC) Select
Alternative Protein Source (APS) LB (Becton Dickinson, Erembo-
degem, Belgium) top agar (0.7%) and a bacteriophage sensitive
bacterial suspension (end concentration of 108 cfu/ml) in a sterile
14 ml tube. This mixture was plated onto ten 90 mm diameter
Petri dishes filled with a bottom layer of 1.5% APS LB agar and
incubated at 37uC for 16–18 h. Subsequently, 200 ml of
chloroform was added to the lids of the Petri dishes and further
incubated at 4uC for 1 h. The top agar layer was scraped off using
a sterile Drigalski spatula (L-shaped rod) and transferred to a
sterile 14 ml tube. The mixture was centrifuged for 20 min at
6 000 g. The supernatant was aspirated using a sterile 10 ml
syringe (BD Plastipak, Becton Dickinson) with a 30 G sterile
needle (BD microlance 3, Becton Dickinson) and passed through a
0.45 mm membrane filter.
Selection of therapeutic bacteriophages
Large 24.5 cm square Petri dishes (Nunc, Wiesbaden, Ger-
many) with 2% LB agar were inoculated with the target bacteria
(108 cfu/ml LB broth). Each target bacterium was applied in one
horizontal strip. As a consequence, the dish contained multiple
parallel inoculation strips. Each strip was air-dried and spotted
with 5 ml of 107 pfu/ml of each of the bacteriophage suspensions
under consideration. The dish was incubated for 16–18 h at 37uC.
The obtained lysis zones were evaluated and scored as cl
(confluent lysis), ol (opaque lysis), scl (semi-confluent lysis), sp
(several plaques) and – (negative reaction).
Composition and endotoxin purification of the
bacteriophage cocktail
Each of the three bacteriophage stock suspensions (PNM, 14/1
and ISP) of the final cocktail was diluted into 100 ml of a sterile
0.9% NaCl solution (B. Braun, Diegem, Belgium) to a final
concentration of 3.109 pfu/ml. Subsequently, the three bacterio-
phage suspensions were mixed in a sterile 500 ml PETG NalgeneH
bottle (Nalge Europe, Neerijse, Belgium) to obtain a 300 ml
volume of the bacteriophage cocktail (named BFC-1), which
contained each bacteriophage at a concentration of 109 pfu/ml.
BFC-1 was subsequently purified from endotoxins using a
commercially available kit (EndoTrapH Blue, Cambrex BioSci-
ence, Verviers, Belgium), according to the instructions of the
manufacturer. One column was utilised per 50 ml of BFC-1.
Endotoxin purified BFC-1 was collected into a sterile 500 ml
PETG NalgeneH bottle and aliquoted into 3 ml doses in sterile
4 ml vials (Brand, We¨rtheim, Germany). The final titre of each
phage was approximately 1.109 pfu/ml.
Final quality control
pH. The pH of BFC-1 was determined by an accredited
laboratory (SGS Lab Simon AS, Brussels, Belgium) in accordance
to the European Pharmacopoeia standards (EP6).
Pyrogenicity
Pyrogenicity was tested by an accredited laboratory (SGS Lab
Simon SA) in accordance with the European Pharmacopoeia
standards (EP6). A sample of 1.2 ml BFC-1 was intravenously
injected in three rabbits. The calculation of the rabbit injection
volume in order to achieve the maximum safety level was done
according to the following equation: rabbit injection volume=hu-
man injection volume x safety factor x rabbit weight/70, with human
injection volume=3 ml - whereby 3 ml is the maximal volume
topically applied in the clinical trial and immediate and complete
resorption is assumed, to achieve maximal safety; with safety
factor=8 (i.e. maximum safety level) and with rabbit weight=3.5 kg.
Sterility
Ten percent of the BFC-1 production was tested for sterility by
an accredited laboratory (Laboratoire de Controˆle et d’Analyses,
Brussels, Belgium) using the membrane filtration method followed
by two weeks of incubation at 37uC, in accordance to the
European Pharmacopoeia (EP6).
Transmission electron microscopy
Bacteriophage particles, with and without target bacteria were
analysed by transmission electron microscopy as described by
Imberechts et al. [29]. Briefly, suspensions were brought on
Bacteriophage Cocktail
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carbon and pioloform-coated grids (Agar Scientific, Stansted, UK),
washed with water and negatively stained with 2% uranyl acetate
(Agar Scientific) in water and analyzed using a Technai Spirit
transmission electron microscope (FEI, Eindhoven, The Nether-
lands) operating at 120 kV. Micrographs were recorded using a
bottom-mounted digital camera (Eagle, 4X4K, FEI).
Exclusion of temperate bacteriophages from the host
strains
To confirm the absence of temperate bacteriophages, originat-
ing from the bacterial hosts used to grow the three lytic
bacteriophages, a standard technique for bacteriophage induction
using the DNA-damaging antimicrobial agent mitomycin C was
carried out, as described by Miller [30].
The host strains used in BFC-1 production (P. aeruginosa strain
573 and S. aureus strain 13 S44 S, as well as the P. aeruginosa
reference strain ‘PAO1’) were grown in APS LB broth at 37uC
until the early exponential growth phase. Bacterial cultures were
aliquoted in 1 ml volumes in sterile eppendorf tubes, covered with
aluminium foil thus protecting the bacteria from photoreactivation
of drug-induced DNA damage. Mitomycin C (Sigma-Aldrich) was
added to final concentrations of 1 or 5 mg/ml [30]. A control tube
without mitomycin C was added to evaluate the presence of ‘non-
drug-induced’ bacteriophages. The tubes were incubated for 3 h at
37uC. Subsequently, twenty ml of chloroform was added to the
control tubes to lyse the bacteria. The lysates were centrifuged in
order to separate the intact bacterial cells from the supernatant. The
final titre of bacteriophages in the supernatant was determined using
the double agar overlay method, as described above.
Genome sequencing and proteomic analysis
DNA from bacteriophages was isolated using a commercially
available kit (Lambda Mini Kit, Qiagen, Hilden, Germany).
Purified DNA from bacteriophages 14/1, PNM and ISP was
sonicated for 1 s at 20% intensity using a Sonics Vibracell and
separated on a 1% agarose gel (Eurogentec, Seraing, Belgium).
Fragments between 1000 and 2000 bp were excised from the gel
(Qiagen, Venlo, The Netherlands), end repaired using Klenow -
T4 polymerase mixture (Fermentas, St.-Leon-Rot, Germany) and
phosphorylated using T4 polynucleotide kinase (Roche, Vilvoorde,
Belgium). Subsequently, fragments were ligated using T4 ligase
(Fermentas) into SmaI-linearised pUC19 plasmids and transformed
to Escherichia coli XL1 blue MRF. This resulted in over 10 000
positive clones after blue white screening for each bacteriophage,
of which more than 90% contained inserts between 1 and 2 kb.
Plasmids from individual clones were isolated and sequenced using
the standard M13f vector primer. After standard ethanol
precipitation, samples were separated and analyzed on an ABI
3130 capillary sequencing device (Applied Biosystems, Lennik,
Belgium). To complete the genomes (sequenced from each strand
for each position), standard primer walking was used. Sequence
assembly into contigs was performed using Sequencher 4.1
software (Gene Codes Corporation, Ann Arbor, USA). ORF
predictions were made using comparative genomics approaches
(tBLASTx), searching for conserved gene products between closely
related phages (14-1 vs F8, PNM vs phiKMV and ISP vs G1). To
scan the genomes for known toxins/lysogeny-related genes,
sequence similarity searches were performed against the non-
redundant nr NCBI database.
Cytotoxicity towards keratinocytes
The effect of BFC-1 on the proliferation of primary neonatal
human foreskin keratinocytes was evaluated in triplicate, using the
trypan blue dye exclusion test. Keratinocytes (nFS02-006, passage
8) were seeded at a concentration of 2500 keratinocytes per cm2 in
24 ml EpilifeTM basal growth medium (Cascade Biologics,
Invitrogen, Merelbeke, Belgium) in six 75 cm2 cell culture flasks
(Falcon, Becton Dickinson). One ml of BFC-1 was added to three
flasks and 1 ml of sterile physiologic water was added to the three
remaining flasks as a control. Flasks were incubated at 37uC, 5%
CO2 and a relative humidity (RH) of 95% for 5 days without
medium change. Three ml of 0.025% trypsin in 0.01% EDTA
solution (Lonza, Verviers, Belgium) was added to the flasks. After
incubation at 37uC in 5% CO2 and 95% RH for 4 min, three
millilitres of 0.025% trypsin inhibitor (Sigma-Aldrich) was added
and mixed by pipetting. The keratinocyte suspension was collected
in a 15 ml tube (Falcon, Becton Dickinson) and centrifuged at
170 g for 10 min. The pellet was resuspended in 5 ml EpilifeTM
basal growth medium. Subsequently, 100 ml of cell suspension was
mixed with 100 ml of a trypan blue staining solution (Biochrom
AG, Berlin, Germany) and the living (colourless) and dead (blue)
cells were counted using a Bu¨rker cell counting chamber and an
inverted microscope (TMS-F, Nikon, Belgium). The mean ratio of
dead keratinocytes versus the total number of keratinocytes,
expressed in %, compared to the control group, was taken as a
measure for the cytotoxicity of BFC-1.
Stability at 4uC
The stability of a dedicated batch of BFC-1 was monitored on a
monthly basis, by determining the titre of each of the three
bacteriophages after storage at 4uC. Taking into account test result
deviations, inherent to bacteriological methods, titres within a
range of 1.108 to 1.1010 pfu/ml confer retention of activity and
thus stability.
Stability after spraying
One ml of BFC-1 was aspired in a 2 ml syringe. A spraying
head with pore size of 300 mm was fixed onto the syringe and the
total volume of cocktail in the syringe was sprayed into a 50-ml
tube. Phage titres were determined prior to and after spraying by
the double agar overlay method.
Batch record file
A batch record file was compiled and checked for conformity to
the product information file by an industrial pharmacist. Principal
aspects contained in the batch record file include:
– the positive advice of the leading ethical committee that
approved the BFC-1 clinical study;
– the BFC-1 product information file, which describes, in detail,
the production process and the characteristics of BFC-1;
– the material transfer and confidentiality disclosure agreement
signed by all partners;
– the filled out working instructions describing all BFC-1
production steps;
– the quality and analysis certificates of all products, materials
and equipment (e.g. bench flow), used in the production of
BFC-1;
– the results and analysis certificates of all final quality control
tests; and
– the labels of the BFC-1 vials.
Clinical application
Prior to patient application, 3 ml of BFC-1 was aspirated
from a ‘single use only’ vial (Figure 2) using a sterile 5 ml
Bacteriophage Cocktail
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syringe (B. Braun) with a sterile 20 G620 needle (Terumo
Europe, Leuven, Belgium). The needle was replaced by a sterile
spray nozzle (actuator V04.1313 BC/NR with micromist insert
V06.203, Robertpack Engineering B.V., Zwolle, The Nether-
lands). BFC-1 was sprayed on the infected burn wound
(Figure 3).
Results
Selection and host range activity of therapeutic
bacteriophages
The activity of 82 P. aeruginosa and 8 S. aureus bacteriophages
from the collections of the Eliava Institute for Bacteriophage,
Figure 2. The final product, a defined bacteriophage cocktail.
doi:10.1371/journal.pone.0004944.g002
Figure 3. Application of BFC-1 on an infected burn wound using a syringe spray.
doi:10.1371/journal.pone.0004944.g003
Bacteriophage Cocktail
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Microbiology and Virology (EIBMV), Tbilisi, Georgia and the
State Institute of Genetics and Selection of Industrial Micro-
organisms (SIGSIM), Moscow, Russia was determined against a
total of 113 P. aeruginosa and 99 S. aureus strains, isolated from
different clinical and environmental habitats across the world. The
complete data on used strains and phages is shown in Table S1.
Eight bacteriophages (PT6, PT8, PNM, 14/1, 9/3, F77, PL and
ISP) were selected for further matching against 23 P. aeruginosa and
17 S. aureus strains, recently isolated from patients at the Burn
Centre of the Queen Astrid Military Hospital in Brussels. The data
on strains and phages tested are shown in Table S2. This resulted
in the selection of three bacteriophages that exhibited a large host
range activity, specific for the burn wound isolates: PNM, 14/1
and ISP (Table 1).
P. aeruginosa bacteriophage PNM, a member of the Podoviridae
family, was isolated in 1999 from the Mtkvari river in Tbilisi, P.
aeruginosa bacteriophage 14/1, a member of the Myoviridae family,
was isolated by Victor Krylov in 2000 from sewage water in
Regensburg, Germany and S. aureus bacteriophage ISP, also a
member of the Myoviridae, was isolated from the Intravenous
Staphylococcal Phage (ISP) preparation produced by the EIBMV
in the 1970s. ISP was initially isolated in the 1920s from an
unknown source in Tbilisi, Georgia.
Quality control parameters verified for this cocktail included
sterility, pyrogenicity and pH stability, evaluated as described in
the materials and methods section and further specified in
Table 2.
Transmission electron microscopy
Microscopy confirmed that BFC-1 only contained bacterio-
phage particles with the expected morphology (Figure 4) and the
expected target strain activity.
Different types of particles were observed consisting of a non-
enveloped head with icosahedral symmetry and a tail with helical
Table 1. Characteristics of the three lytic bacteriophages present in BFC-1.
Phage 14/1 PNM ISP
Host species P. aeruginosa P. aeruginosa S. aureus
Initial source Sewage water Mtkvari River Unknown
Initial place of isolation Regensburg, Germany Tbilisi, Georgia Tbilisi, Georgia
Initial date of isolation 2000 1999 1920–1930
Isolated by V. Krylov (SIGSIM) N. Lashki & M. Tediashvili (EIBMV) from ISPa
Serogroup E PT5, PNC101 ISP
Genome size (kb) 66.1 42.4 120
Family of Caudovirales Myoviridae A1 Podoviridae C1 Myoviridae A1
Host range activity (%)
All strains 37 44 91
BWC strains 83 96 100
aISP: Intravenous Staphylococcal Phage (ISP) preparation produced by Eliava IBMV. Phage ISP was isolated from this preparation in the 1970s.
doi:10.1371/journal.pone.0004944.t001
Table 2. Summary of the quality control test results.
Test Specifications Method BFC-1 test result
pH 6.0–8.0 pH test (EP6) 7.0 (conform)
Pyrogenicity #1.15uC temperature rise Intravenous injection in 3 rabbits (EP6) 0.5uC (conform)
Sterility Sterile Membrane filtration method (EP6) Sterile (conform)
Cytotoxicity No cytotoxicity, no growth inhibition,
no morphology changes
Co-culture with human keratinocytes No cytotoxicity (conform), no growth
inhibition (conform), no morphology
changes (conform)
Activity (titre) log(8)–log(10) pfu/ml Bacteriophage titration 8 log(8)–log(9) pfu/ml (conform)
Morphology of the bacteriophages 2 Myoviridae and 1 Podoviridae Transmission electron microscopy 2 Myoviridae and 1 Podoviridae (conform)
Recognition of targeted bacteria Specific recognition Transmission electron microscopy One Myo- and one Podoviridae member
recognize and kill P. aeruginosa. The other
Myoviridae member recognizes and kills S.
aureus (conform)
Phage intactness Absence of
cellular debris
Intact, pure Transmission electron microscopy Pure (conform)
Temperate bacteriophages in host
strains
Total absence Mitomycin C induction of temperate
bacteriophages
Total absence (conform)
Lytic nature Lytic DNA sequence and proteome analysis Lytic (conform)
Presence of toxic proteins No toxic proteins DNA sequence and proteome analysis No predicted toxic proteins (conform)
doi:10.1371/journal.pone.0004944.t002
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symmetry. These characteristics are consistent with the attributes
of the bacteriophage order Caudovirales.
One type of particles had an isometric hexagonal head with a
diameter of 60 nm and a straight, short, thick, non-contractile tail
built of stacked non-banded rings. The tail had a length of 10 nm
and a width of approximately 8 nm. Subterminal fibers were short
and difficult to visualize. These characteristics attribute this type of
bacteriophages to the Podoviridae family.
Two morphotypes of Myoviridae could be distinguished, based on
the respective sizes of the head and the length of the (non-
contracted) tail. One population had a head diameter of
approximately 78 nm and a tail length of 100 nm, whereas a
second morphotype had a head diameter of approximately 90 nm
and a tail length of approximately 175 nm.
When BFC-1 was combined with cultured S. aureus and P.
aeruginosa bacteria, bacteriophages from the Podoviridae and the
Myoviridae adsorbed to (and killed) their respective host.
The material observed in BFC-1 was pure, consisting almost
entirely of (exculsively lytic) bacteriophages, or bacteriophage-
derived material (isolated tails, heads, etc). No other etiological
agents or residual bacteria were observed.
DNA sequencing and in silico proteomic analysis
The complete genome sequences of the two P. Aeruginosa
infecting phages 14/1 and PNM were determined by a
combination of shotgun sequencing and primer walking as
described in Experimental Procedures. The genome of 14/1
comprises 66.2 kb and has a G+C content of 55.6%, which is
significantly lower than that of its host (66.6%).
Sequence analysis showed that bacteriophage 14/1 is a close
relative of bacteriophage F8 (66 kb) [31], having an overall DNA
identity of 87% (total average), spread throughout the genome.
Bacteriophage F8 is one of the original Lindberg Pseudomonas
typing phages. Among the 90 predicted gene products of 14/1 (or
corresponding homologsin F8 or F8-like bacteriophages like
BcepF1 or BcepB1A) no toxic proteins are present and the
genome does not contain a recognizable integrase gene, corrobo-
rating the lytic nature of these bacteriophages. Indeed, an initial
screen revealed a single, potentially toxic gene (VirE) within the
genome of phage 14/1 (NC_011703). However, the BCep1 VirE
homologue was recently connected to the prim-pol primase
superfamily of DNA polymerases, implying a role in phage DNA
replication for VirE, rather than promoting host pathogenicity.
Figure 4. BFC-1 transmission electron micrographs. a) S. aureus bacteriophage ISP, a member of the Myoviridae family. Bar: 100 nm. b) PNM
bacteriophages (Podoviridae) freed from a burst P. aeruginosa bacterium. Bar: 500 nm. c) Bacteriophage 14/1 attaching to the P. aeruginosa cell wall.
Bar: 200 nm. d) ISP bacteriophages (Myoviridae) attached to S. aureus. Bar: 500 nm.
doi:10.1371/journal.pone.0004944.g004
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The genome of PNM is 42.7 kb and with its 62.3% it
approximates the host G+C content.
The bacteriophage PNM genome shows close homology to
wKMV, with only minor (single nucleotide) differences between
PNM and wKMV, located in the DNA replication and structural
region (average homology .95%). Differences are most obvious in
the early region (80–90% DNA homology), which is consistent
with the known genomic variations between the members of the
wKMV-like bacteriophages [32]. To date, proteomic character-
ization of wKMV-like viruses has not revealed any toxic gene
products present in these bacteriophages [32,33], indicating their
absence in PNM.
For bacteriophage ISP, the 816 sequencing runs on shotgun
clones yielded a total of 120 kb of unique sequences, 100 kb of
which is contained within contigs. This represents about 86% of
the predicted genome length of about 140 kb. Preliminary analysis
of the ISP genome data suggests that this bacteriophage is almost
identical to S. aureus bacteriophage G1 (over 99% DNA
homology). The homology of bacteriophage ISP to bacteriophages
G1 and K is interesting from a therapeutic perspective, since these
bacteriophages have been used in several clinical settings and
animal studies [34,35].
Physicochemical properties of BFC-1
The pH of BFC-1 was 7.0, which is within specifications (6.0–
8.0 pH).
Since ten percent of the BFC-1 production was found to be
sterile as assessed by the membrane filtration method, the product
was considered to conform to the European Pharmacopoeia
standards (EP6).
The monthly titration of the separate bacteriophages in BFC-1
showed a conservation of 100% of the initial activity (1.109 pfu/
ml) for at least 12 months and further testing is ongoing.
Toxicity and pyrogenicity of BFC-1
No cytotoxicity towards human neonatal foreskin keratinocytes
was observed. The addition of BFC-1 to the culture medium had
no impact on the viability of the keratinocytes (Table 3). The
proliferation rate of the keratinocytes, represented by the mean
cell number after 5 days of culture (Table 3), was not inhibited,
and the morphology of the keratinocytes was not altered by the
bacteriophages. Keratinocyte cultures, with and without BFC-1,
reached 80–90% confluence after 5 days of culture whilst
maintaining a normal morphology.
Since the sum of the increase of body temperature after
injection of 1.2 ml of BFC-1 in the three rabbits was 0.5uC, which
is much lower than the allowed increase of 1.15uC, the product
was found to conform to the European Pharmacopoeia standards
(EP6).
Table 2 summarizes the tests, specifications, methods and
results of the final quality control.
Discussion
Phage therapy has the potential to be one of the promising
alternatives/complements to antibiotics. In the past, this approach
was often not as effective as hoped. Reasons for this included the
empirical use of poorly characterised crude bacteriophage
preparations. In addition, the clinical application of bacteriophag-
es for treatment of infections of humans in modern western
medicine is stuck in a vicious regulatory circle [14]. Under the
current regulatory framework, bacteriophages do not exist because
of the lack of clinical trials - yet to perform these trials one needs a
regulatory existence. As such, the development of a well-
characterized bacteriophage preparation using GMP (Good
Manufacturing Practices)-like procedures was warranted for
scientific and medico-legal reasons.
All products used in the production of BFC-1, were certified or
accompanied by an adequate certificate of analysis and were fully
compatible with the topical application on burn wound patients.
In addition, all equipment (e.g. pipettes, bench flow and
incubators) used in the production of BFC-1 was calibrated and
certified. Apart from the bacteriophages (PNM, 14/1 and ISP),
BFC-1 is composed of sterile and apyrogenic water (aqua ad
injectabilia as required by the European Pharmacopoeia) as solvent,
supplemented with 0.9% w/w NaCl for adaptation to physiologic
osmotic strength.
The minimal bacteriophage titres required for the intended
clinical applications are unknown. Bacterial loads of 105 bacteria
per g wound tissue were shown to confer a septicaemic risk [36].
Our choice of 109 pfu/ml of each bacteriophage, applied in doses
of 1 ml per 50 cm2 wound bed, should result in concentrations of
at least 100 bacteriophages for each target bacterium.
Since it cannot be excluded that BFC-1 also contains traces of
the initial bacterial growth medium and since traditional growth
media for bacteria contain animal extracts (implying a risk of
transmission of infectious agents such as BSE), it was decided to
use a bacterial growth medium certified to be free of animal
proteins. The most important medium remnants in BFC-1 are soy
hydrolysate and yeast extract, inherent components of the Select
APS LB Broth Base used for bacterial growth and bacteriophage
production. The theoretical final concentrations of these rem-
nants, before endotoxin removal, are 25 and 125 mg/ml of BFC-1
respectively.
Phage therapy faced several problems often due to an
inadequate preparation methodology. Purification, removal of
endotoxins and pyrogenic substances, stability and pH control of
the preparation were rather problematic in the past [6].
Endotoxins possess a high degree of toxicity, and their removal
is essential for safety in antibacterial bacteriophage therapy [37].
BFC-1 was easily and successfully purified from endotoxins using
a commercially available, column endotoxin purification kit,
which is based on the principles of affinity chromatography. The
high endotoxin affinity ligand of the EndoTrapH Blue affinity
matrix is proteinaceous and derived from a bacteriophage. It is
Table 3. Results of cytotoxicity testing.
Without BFC-1
Culture flask Cell number (log6) Viability (%)
1 2.00 90.9
2 2.23 89.3
3 2.10 85.1
Mean: 2.11 88.5
Standard deviation: 1.17 3.0
With BFC-1
4 1.90 93.4
5 2.30 90.8
6 2.33 89.7
Mean: 2.18 91.3
Standard deviation: 2.41 1.9
doi:10.1371/journal.pone.0004944.t003
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not an antibody, and is covalently immobilized on agarose beads
in order to ensure negligible leakage.
Accredited laboratories, able to deliver certified results,
performed the final quality control tests such as determination
of pH, pyrogenicity and sterility, classically required in clinical
studies. An in-house cytotoxicity test was performed. For
endotoxin testing, the Limulus Amoebocyte Lysate (LAL) assay
is the regulatory first line test (EP6, chapter 2.6.14/11.2). The
reference laboratory to which the cocktail was sent for
pyrogenicity testing first attempted to apply the LAL assay, but
the phages appeared to interfere with this test. The rabbit
pyrogenicity test can be used only when there is interference with
the endotoxin test, which was the case here. In fact the
pyrogenicity test encompasses all pyrogens and not only
endotoxins. We applied the real volumes that were to be applied
on patients and took the largest safety factor for acceptability of
the phage cocktail.
In theory, there is no need to ascertain the absence of pyrogens
from products, which are not intravenously/parenterally admin-
istered. However, we worked with a product that during its
production process was in close contact with bacteria and that by
application to a burn wound could diffuse partially into the blood
stream.
The pH is a homeostasis and stability indicator and thus an
important parameter of a therapeutic product. A pH between 6.0
and 8.0 guarantees the stability of infectivity of the bacteriophages
[38] and is compatible with the wound bed physiology [39]. The
pH 7.0 of BFC-1 (ideal for stable storage) is suitable for topical use
on burn wounds.
According to guideline Q5C (Quality of Biotechnological
Products: Stability Testing of Biotechnological/Biological Prod-
ucts), published by the International Conference on Harmonisa-
tion of Technical Requirements for Registration of Pharmaceu-
ticals for Human Use (ICH), the manufacturer should propose a
stability indicating profile to ensure that changes in the identity,
purity and potency of the product will be detected. Since BFC-1
consists of three bacteriophages suspended in a physiological
solution and is stored at 2–8uC in 3 ml ‘single use only’ vials,
identity and purity are not considered likely to alter. In this
particular case, the parameter that is thus proposed to profile the
stability characteristics of BFC-1 is the activity or potency of the
sole active components of BFC-1, the bacteriophages PNM, 14/1
and ISP. The slightest deterioration of one or all of the
bacteriophages will immediately result in a decrease of the
capacity to achieve its intended effect ( = activity or potency) of
BFC-1. This capacity was measured through titration of the
bacteriophages against the host strains that were used to propagate
the phages. BFC-1 was shown to maintain 100% of its initial
activity after storage at 4uC for at least one year. Further follow-up
of stability testing is ongoing.
Since temperate bacteriophages are known to transfer
antibiotic resistance and virulence genes from one bacterium
to another, a process known as lysogenic conversion, the absence
of temperate bacteriophages from the host bacteria used in the
production of BFC-1 had to be confirmed. The chemical
induction test suggested an absence of temperate bacteriophages
and the DNA sequence and proteomic analysis confirmed the
lytic character of the bacteriophages and the absence of toxin
genes. Transmission electron microscopy confirmed the phage
particle intactness and expected morphology as well as the
absence of cellular debris.
The host specificity of the phages could be established by means
of electron microscopy as well.
Data documenting the BFC-1 production process and the
certified quality control tests on the final product were compiled
into a batch record file. An industrial pharmacist certified the
conformity of this file to the product information file.
BFC-1 is currently evaluated in a clinical trial, which was
approved by the Ethical Committee of the ‘‘Universitair
Ziekenhuis’’ of the ‘‘Vrije Universiteit Brussel’’ and started in
October 2007. To date, BFC-1 has been applied topically
(Figure 3) on the infected burn wounds of eight patients. No
adverse events were observed.
This is, to our knowledge, the first detailed description of a
quality-controlled small-scale production of a bacteriophage
preparation, leading to a safety trial in burn wound patients,
which was approved by a leading Belgian ethical committee. The
aim of this manuscript was therefore not to produce a commercial
product, or to assess regulatory aspects of phage therapy, but
merely implementing a small step in the further evaluation of
phage therapy in Western medicine.
Together with European experts, we are currently in the process
of creating a discussion platform that could act as one of the
interlocutors with the regulatory authorities (e.g. EMEA) for the
creation of a specific regulatory framework and appropriate
production standards for phage therapy. Another, equally
important objective is to help provide the necessary studies to
enable a coherent use of phage therapy.
Supporting Information
Table S1 Activity of phages against 113 P. aeruginosa and 99 S.
aureus strains, isolated from different clinical and environmental
habitats across the world.
Found at: doi:10.1371/journal.pone.0004944.s001 (0.25 MB
XLS)
Table S2 Activity of phages against 23 P. aeruginosa and 17 S.
aureus strains, recently isolated from patients at the Burn Centre of
the Queen Astrid Military Hospital in Brussels.
Found at: doi:10.1371/journal.pone.0004944.s002 (0.03 MB
XLS)
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